ESSEXBIO-TECH：INTERIMREPORT2022.pdf

1、2022 INTERIMREPORTPIONEERING GLOBALREGENERATIVESCIENCE&TECHNOLOGYTOMORROWS TODAY2Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income3Condensed Consolidated Statement of Financial Position4Condensed Consolidated Statement of Changes in Equity5Condensed Consolidated State

2、ment of Cash Flows7Notes to the Interim Condensed Consolidated Financial Statements25Management Discussion and Analysis40Additional Information44Corporate InformationCONTENTSESSEX BIO-TECHNOLOGY LIMITED2The board(the“Board”)of directors(the“Directors”)of Essex Bio-Technology Limited(the“Company”)pre

3、sents the unaudited interim condensed consolidated financial statements of the Company and its subsidiaries(collectively,the“Group”)for the six months ended 30 June 2022 together with the comparative figures for the corresponding period in 2021 and the relevant explanatory notes as set out below.CON

4、DENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOMEFor thesix monthsended 30 June20222021(Unaudited)(Unaudited)NotesHK$000HK$000 Turnover4&5655,825737,374Cost of sales(69,181)(114,680)Gross profit586,644622,694Other revenue,and other gains and losses624,08112,083Distributi

5、on and selling expenses(363,808)(377,280)Administrative expenses(79,564)(69,061)Finance costs7(4,652)(5,362)Profit before income tax8162,701183,074Income tax9(23,470)(20,888)Profit for the period139,231162,186 Other comprehensive incomeItems that may be reclassified subsequently to profit or loss:Ex

6、change differences on translation of financial statements of foreign operations(78,111)18,586Items that will not be reclassified subsequently to profit or loss:Changes in fair value of equity instruments at fair value through other comprehensive income(15,090)(560)Other comprehensive income for the